Breaking News
Get 40% Off 0
🔎 See NVDA's full ProTips for an instant risks or rewards Claim 40% OFF
Close

Destiny Pharma PLC (DEST)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
40.10 -1.90    -4.52%
11:49:38 - Real-time Data. Currency in GBP ( Disclaimer )
  • Volume: 87,160
  • Bid/Ask: 40.00 / 41.00
  • Day's Range: 40.10 - 42.00
Type:  Equity
Market:  United Kingdom
ISIN:  GB00BDHSP575 
SEDOL:  BDHSP57
Destiny Pharma 40.10 -1.90 -4.52%

Destiny Pharma PLC Company Profile

 
Read the Destiny Pharma PLC company profile to learn more about the business and the management team. View employee data, company address and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

24

Equity Type

ORD

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Research/Biofilms that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, dermal, oral and ocular infections. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; Sebela Pharmaceuticals; the University of Southampton; Aston University; the University of Sheffield; National Biofilms Innovation Centre; National Institute of Allergy and Infectious Diseases; Cystic Fibrosis Foundation; Cardiff University; and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.

Contact Information

Address Sussex Innovation Centre Unit 36
Science Park Square Falmer Brighton, BN1 9SB
United Kingdom
Phone 44 1273 704440
Fax -

Top Executives

Name Age Since Title
Anthony N. Russell Rudd 77 2016 Chairman
William Guy Love 60 1997 Founder, Chief Scientific Officer & Director
Shaun Claydon 54 2018 CFO, Company Secretary & Director
Aled Paton Williams 53 2022 Non-Executive Director
Richard Proctor - 2018 Member of Scientific Advisory Board
Vance Garrison Fowler - 2018 Member of Scientific Advisory Board
Glenn J. R. Whitman - 2018 Member of Scientific Advisory Board
Leonard Alan Mermel - 2018 Member of Scientific Advisory Board
Nigel Stanley Brooksby 72 2022 Non-Executive Director
E Patchen Dellinger - - Member of Scientific Advisory Board
James Patrick Stearns 44 2022 Non-Executive Director
Mark H. Wilcox - 2021 Member of Scientific Advisory Board
Dale N. Gerding - 2020 Member of Scientific Advisory Board
David Roblin 57 2011 Chair of the Scientific Advisory Board
Debra Barker 61 2020 Interim CMO & Senior Independent Director
Christopher John Tovey 58 2023 CEO & Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

DEST Comments

Write your thoughts about Destiny Pharma PLC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Martyn Turner
Martyn Turner Oct 17, 2023 13:21
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This great new data could lead to special things. Expecting a deal to land.
Peter Ball
Peter Ball Jul 28, 2023 16:24
Saved. See Saved Items.
This comment has already been saved in your Saved Items
on the way up
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email